MedTrace Logo

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients

NCT02944214 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2016-10-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function in chinese, and which one could be better.

Conditions

Interventions

DRUG

Febuxostat

It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body

DRUG

Benzbromarone

It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase

Sponsors & Collaborators

  • Shanghai 10th People's Hospital

    lead OTHER

Principal Investigators

  • Ai Peng, MD, PhD · Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02944214 on ClinicalTrials.gov